3D Global Biotech (TPEX:6808) - Stock Price, News & Analysis

6808 Stock Overview

Develops medical materials for human body reconstruction in China. More details

6808 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 4.7% per year over past 5 years

Shareholders have been diluted in the past year

Does not have a meaningful market cap (NT$3B)

Does not have meaningful revenue (NT$55M)

3D Global Biotech Inc. Competitors

UnicoCell Biomed

TWSE:6794

NT$4.3b

Great Novel Therapeutics Biotech & Medicals

TPEX:7427

NT$1.6b

Senhwa Biosciences

TPEX:6492

NT$4.1b

TaiRx

TPEX:6580

NT$3.3b

Price History & Performance

Summary of all time highs, changes and price drops for 3D Global Biotech
Historical stock prices
Current Share Price	NT$40.25
52 Week High	NT$44.95
52 Week Low	NT$18.80
Beta	0.43
11 Month Change	-1.47%
3 Month Change	7.19%
1 Year Change	109.09%
33 Year Change	21.23%
5 Year Change	n/a
Change since IPO	-20.61%

Recent updates

Shareholder Returns

	6808	TW Biotechs	TW Market
7D	11.5%	-3.1%	-0.8%
1Y	109.1%	2.0%	29.0%

Return vs Industry: 6808 exceeded the TW Biotechs industry which returned 2% over the past year.

Return vs Market: 6808 exceeded the TW Market which returned 29% over the past year.

Price Volatility

Is 6808's price volatile compared to industry and market?
6808 volatility
6808 Average Weekly Movement	4.6%
Biotechs Industry Average Movement	4.5%
Market Average Movement	4.5%
10% most volatile stocks in TW Market	8.0%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6808 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6808's weekly volatility (5%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	33	n/a	www.3dglobalbiotech.com.tw

3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts professional research.

3D Global Biotech Inc. Fundamentals Summary

How do 3D Global Biotech's earnings and revenue compare to its market cap?
6808 fundamental statistics
Market cap	NT$3.09b
Earnings (TTM)	-NT$29.41m
Revenue (TTM)	NT$55.15m

56.1x

P/S Ratio

-105.1x

P/E Ratio

Is 6808 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6808 income statement (TTM)
Revenue	NT$55.15m
Cost of Revenue	NT$19.79m
Gross Profit	NT$35.36m
Other Expenses	NT$64.77m
Earnings	-NT$29.41m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.38
Gross Margin	64.12%
Net Profit Margin	-53.32%
Debt/Equity Ratio	0%

How did 6808 perform over the long term?

See historical performance and comparison

3D Global Biotech TPEX:6808 Stock Report